Vivos Therapeutics, Inc. (VVOS) — 8-K Filings

8-K Filings (28)

• Vivos Therapeutics Files 8-K for Financial Update — Apr 15, 2026 Risk: medium
  Vivos Therapeutics, Inc. filed an 8-K on April 15, 2026, reporting on its Results of Operations and Financial Condition. The filing also includes Financial Stat
• Vivos Therapeutics Files 8-K: Other Events & Exhibits — Dec 17, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on December 16, 2025. The filing indicates "Other Events" and "Fin
• Vivos Therapeutics Files 8-K on Definitive Agreement — Dec 5, 2025 Risk: medium
  On December 5, 2025, Vivos Therapeutics, Inc. filed an 8-K report detailing the entry into a material definitive agreement and the creation of a direct financia
• Vivos Therapeutics Files 8-K on Security Holder Vote Matters — Nov 4, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on November 4, 2025, to report on the submission of matters to a vote of security holders. The filing details the company'
• Vivos Therapeutics Files 8-K — Oct 24, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on October 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• Vivos Therapeutics Updates Principal Office Address — Sep 18, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting an event on September 17, 2025. The filing indicates a change in the company's principal
• Vivos Therapeutics Files 8-K — Sep 12, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on September 12, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Vivos Therapeutics Files 8-K on Financials — Aug 20, 2025 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Vivos Therapeutics Files 8-K: Agreements, Debt, and Equity Sales — Jun 13, 2025 Risk: medium
  On June 9, 2025, Vivos Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of
• Vivos Therapeutics Appoints New Auditor — Jun 6, 2025 Risk: low
  Vivos Therapeutics, Inc. announced on June 6, 2025, that it has appointed a new independent registered public accounting firm, CohnReznick LLP, effective June 3
• Vivos Therapeutics Enters Material Agreement, Discloses Equity Sales — May 23, 2025 Risk: medium
  On May 21, 2025, Vivos Therapeutics, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The fi
• Vivos Therapeutics Enters Material Definitive Agreement — Apr 17, 2025 Risk: medium
  Vivos Therapeutics, Inc. announced on April 17, 2025, that it entered into a Material Definitive Agreement on April 15, 2025. The filing details are provided in
• Vivos Therapeutics Files 8-K: Agreements, Officer Changes, Financials — Feb 14, 2025 Risk: medium
  On February 14, 2025, Vivos Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, and t
• Vivos Therapeutics Reports Material Agreement and Equity Sales — Dec 23, 2024 Risk: medium
  On December 23, 2024, Vivos Therapeutics, Inc. reported the entry into a material definitive agreement. The company also disclosed unregistered sales of equity
• Vivos Therapeutics Files 8-K on Shareholder Vote Matters — Nov 27, 2024 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on November 27, 2024, reporting on matters submitted to a vote of security holders on November 26, 2024. The filing detail
• Vivos Therapeutics Enters Securities Purchase Agreement — Sep 20, 2024 Risk: medium
  On September 18, 2024, Vivos Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with certain investo
• Vivos Therapeutics Files 8-K — Sep 18, 2024 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on September 18, 2024, reporting other events and financial statements. The company, formerly Vivos BioTechnologies, Inc.,
• Vivos Therapeutics Reports on Shareholder Nominations — Sep 17, 2024 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on September 17, 2024, reporting on shareholder nominations for its board of directors. The earliest event reported was on
• Vivos Therapeutics Appoints New Director, Discloses Officer Compensation — Sep 12, 2024 Risk: low
  Vivos Therapeutics, Inc. announced on September 12, 2024, a change in its board of directors. Specifically, Dr. Michael J. Rieder has been appointed as a new di
• Vivos Therapeutics Files 8-K on Financials — Aug 15, 2024 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 14, 2024. The filing inclu
• Vivos Therapeutics Files 8-K Report — Jul 10, 2024 Risk: low
  On July 10, 2024, Vivos Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific financial figures or significan
• Vivos Therapeutics Closes $10M Public Offering — Jun 25, 2024 Risk: medium
  On June 25, 2024, Vivos Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised appro
• Vivos Therapeutics Raises $1.5M in Stock Sale — Jun 14, 2024 Risk: medium
  On June 10, 2024, Vivos Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with accredited investors
• Vivos Therapeutics Faces Nasdaq Delisting Concerns — May 17, 2024 Risk: high
  Vivos Therapeutics, Inc. filed an 8-K on May 17, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is facing pot
• Vivos Therapeutics Files 8-K on Financials — May 15, 2024 Risk: medium
  Vivos Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Vivos Therapeutics Sells Subsidiary Vivos Life Sciences — May 6, 2024 Risk: medium
  Vivos Therapeutics, Inc. announced on May 3, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Vivos Life Sciences, Inc
• Vivos Therapeutics Files 8-K on Financials — Mar 29, 2024 Risk: low
  Vivos Therapeutics, Inc. filed an 8-K on March 29, 2024, reporting on events as of March 28, 2024. The filing pertains to Results of Operations and Financial Co
• Vivos Therapeutics Reports Material Agreement & Unregistered Equity Sales — Feb 15, 2024 Risk: medium
  Vivos Therapeutics, Inc. filed an 8-K on February 15, 2024, reporting two key events that occurred on February 14, 2024: the entry into a Material Definitive Ag

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX